Hologic (NASDAQ: HOLX) reported Q1 EPS of $0.46, $0.04 better than the analyst estimate of $0.42. Revenue for the quarter came in at $695.2 million versus the consensus estimate of $688.04 million.

GUIDANCE:

Hologic sees Q2 2016 EPS of $0.45-$0.46, versus the consensus of $0.45. Hologic sees Q2 2016 revenue of $680-690 million, versus the consensus of $695.5 million.

Hologic sees FY2016 EPS of $1.86-$1.90, versus prior guidance of $1.80-$1.84 and the consensus of $1.82. Hologic sees FY2016 revenue of $2.8-2.83 billion, versus prior guidance of $2.81-2.84 billion and the consensus of $2.84 billion.

"We are pleased with our first quarter financial results overall," said Steve MacMillan, Hologic's Chairman, President and Chief Executive Officer. "Our U.S. businesses again performed exceptionally well, with double-digit revenue growth. This contributed to improvement in our already strong operating margin, and earnings per share growth at nearly three times the rate of revenue."

For earnings history and earnings-related data on Hologic (HOLX) click here.